iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data

Philips iFR iFR co-registration October 26, 2023 Safety of Philips’ iFR in the guidance of percutaneous coronary intervention (PCI) for heart disease demonstrated in late-breaking science at TCT 2023 highlighting patient-level outcomes analysis of 42,000 patients from the National Swedeheart Quality RegistryPrevious data demonstrate that iFR delivers consistent patient outcomes, reduces discomfort and offers a more cost-effective and faster diagnostic solution [1,2] compared to FFR Amsterdam, th

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,San Francisco ,California ,United States ,Sweden ,Berntorp ,Blekinge Läsw ,Japan ,American ,Coll Cardiol ,Chris Landon ,American College Of Cardiology ,Lund University ,Philips ,American Heart Association ,Philips Global Press Office ,Society For Cardiovascular Angiography Interventions ,Clinical Sciences ,Department Of Cardiology ,European Society Of Cardiology ,National Swedeheart Quality Registry ,National Swedeheart Quality ,Revascularization Deferral Based ,Instantaneous Wave Free Ratio ,Fractional Reserve ,Cardiovascular Therapeutics ,Gold Standard ,American College ,Cardiovascular Angiography ,European Society ,General Manager ,Philips Image Guided Therapy ,Coronary Artery ,Eur Heart ,Fractional Flow Reserve ,Patient Outcomes ,Interventional Procedures ,Heart Attack ,Longitudinal Analysis ,Health Technology ,Heart Disease ,